InvestorsHub Logo
Followers 0
Posts 122
Boards Moderated 0
Alias Born 03/06/2020

Re: GreenBioAnalyst post# 295863

Thursday, 05/07/2020 2:50:03 AM

Thursday, May 07, 2020 2:50:03 AM

Post# of 403475
Now, this link just came out today!
https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1757510
"Cobicistat, ritonavir, lopinavir, and darunavir are in the top screened molecules from FDA approved drugs. The screened drugs and molecules may be helpful in fighting with SARS-CoV-2 after further studie"
in-silico is helpful for for separating kernels from chaff but trials are the pudding

"A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir–ritonavir group, and 100 to the standard-care group. Treatment with lopinavir–ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir–ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). "
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282

Many here are hoping Brilacidin's membrane disruption ability will also prove effective against CV capsid and envelope. One of the questions to be or being answered is how a synthetic mimic of proteins, such as AMP. will fare as an antiviral.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News